Language:

Tackling COVID-19 with neutralizing monoclonal antibodies

Cell, 2021-06, Vol.184 (12), p.3086-3108 [Peer Reviewed Journal]

2021 Elsevier Inc. ;Copyright © 2021 Elsevier Inc. All rights reserved. ;2021 Elsevier Inc. 2021 Elsevier Inc. ;ISSN: 0092-8674 ;EISSN: 1097-4172 ;DOI: 10.1016/j.cell.2021.05.005 ;PMID: 34087172

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Tackling COVID-19 with neutralizing monoclonal antibodies
Author: Corti, Davide ; Purcell, Lisa A. ; Snell, Gyorgy ; Veesler, David
Subjects: Angiotensin-Converting Enzyme 2 - chemistry ; Angiotensin-Converting Enzyme 2 - immunology ; Angiotensin-Converting Enzyme 2 - metabolism ; Animals ; Antibodies, Monoclonal - chemistry ; Antibodies, Monoclonal - immunology ; Antibodies, Monoclonal - therapeutic use ; Antibodies, Neutralizing - chemistry ; Antibodies, Neutralizing - immunology ; Antibodies, Neutralizing - therapeutic use ; Antibodies, Viral - chemistry ; Antibodies, Viral - immunology ; Antibodies, Viral - therapeutic use ; COVID-19 ; COVID-19 - pathology ; COVID-19 - virology ; COVID-19 Drug Treatment ; Humans ; monoclonal antibody ; neutralization ; Review ; SARS-CoV-2 ; SARS-CoV-2 - immunology ; SARS-CoV-2 - isolation & purification ; SARS-CoV-2 - metabolism ; Spike Glycoprotein, Coronavirus - immunology ; therapeutics
Is Part Of: Cell, 2021-06, Vol.184 (12), p.3086-3108
Description: Monoclonal antibodies (mAbs) have revolutionized the treatment of several human diseases, including cancer and autoimmunity and inflammatory conditions, and represent a new frontier for the treatment of infectious diseases. In the last 20 years, innovative methods have allowed the rapid isolation of mAbs from convalescent subjects, humanized mice, or libraries assembled in vitro and have proven that mAbs can be effective countermeasures against emerging pathogens. During the past year, an unprecedentedly large number of mAbs have been developed to fight coronavirus disease 2019 (COVID-19). Lessons learned from this pandemic will pave the way for the development of more mAb-based therapeutics for other infectious diseases. Here, we provide an overview of SARS-CoV-2-neutralizing mAbs, including their origin, specificity, structure, antiviral and immunological mechanisms of action, and resistance to circulating variants, as well as a snapshot of the clinical trials of approved or late-stage mAb therapeutics. Intense efforts have been made to develop or identify drugs to treat people with COVID-19. Monoclonal antibodies are one of the few types of drugs that have shown efficacy in the clinic.
Publisher: United States: Elsevier Inc
Language: English
Identifier: ISSN: 0092-8674
EISSN: 1097-4172
DOI: 10.1016/j.cell.2021.05.005
PMID: 34087172
Source: Cell Press Free Archives
MEDLINE

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Tackling COVID-19 with neutralizing monoclonal antibodies

2021 Elsevier Inc. ;Copyright © 2021 Elsevier Inc. All rights reserved. ;2021 Elsevier Inc. 2021 Elsevier Inc. ;ISSN: 0092-8674 ;EISSN: 1097-4172 ;DOI: 10.1016/j.cell.2021.05.005 ;PMID: 34087172

Searching Remote Databases, Please Wait